These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 22942429)
1. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice. Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429 [TBL] [Abstract][Full Text] [Related]
2. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543 [TBL] [Abstract][Full Text] [Related]
3. The Role of the N-Terminal Domain of Thrombomodulin and the Potential of Recombinant Human Thrombomodulin as a Therapeutic Intervention for Shiga Toxin-Induced Hemolytic-Uremic Syndrome. Kröller S; Schober J; Krieg N; Dennhardt S; Pirschel W; Kiehntopf M; Conway EM; Coldewey SM Toxins (Basel); 2024 Sep; 16(9):. PubMed ID: 39330867 [TBL] [Abstract][Full Text] [Related]
4. The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin-associated hemolytic uremic syndrome model mice. Suyama K; Kawasaki Y; Miyazaki K; Kanno S; Ono A; Ohara S; Sato M; Hosoya M Nephrol Dial Transplant; 2015 Jun; 30(6):969-77. PubMed ID: 25694534 [TBL] [Abstract][Full Text] [Related]
5. Mouse model for hemolytic uremic syndrome induced by outer membrane vesicles of Escherichia coli O157:H7. Kim SH; Lee YH; Lee SH; Lee SR; Huh JW; Kim SU; Chang KT FEMS Immunol Med Microbiol; 2011 Dec; 63(3):427-34. PubMed ID: 22029600 [TBL] [Abstract][Full Text] [Related]
7. Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome. Orth-Höller D; Würzner R Semin Thromb Hemost; 2014 Jun; 40(4):503-7. PubMed ID: 24799304 [TBL] [Abstract][Full Text] [Related]
8. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Exeni RA; Fernandez-Brando RJ; Santiago AP; Fiorentino GA; Exeni AM; Ramos MV; Palermo MS Pediatr Nephrol; 2018 Nov; 33(11):2057-2071. PubMed ID: 29372302 [TBL] [Abstract][Full Text] [Related]
9. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Geelen JM; van der Velden TJ; Te Loo DM; Boerman OC; van den Heuvel LP; Monnens LA Nephrol Dial Transplant; 2007 Mar; 22(3):749-55. PubMed ID: 17127697 [TBL] [Abstract][Full Text] [Related]
10. Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2. Harrison LM; Gaines DW; Babu US; Balan KV; Reimschuessel R; Do AB; Pereira MR; Bigley EC; Ferguson M; Mehta A; Williams KM Microb Pathog; 2018 Oct; 123():250-258. PubMed ID: 30016681 [TBL] [Abstract][Full Text] [Related]
12. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome]. Ito K; Hattori M; Matsumoto N Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084 [TBL] [Abstract][Full Text] [Related]
13. Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome. Arvidsson I; Ståhl AL; Hedström MM; Kristoffersson AC; Rylander C; Westman JS; Storry JR; Olsson ML; Karpman D J Immunol; 2015 Mar; 194(5):2309-18. PubMed ID: 25637016 [TBL] [Abstract][Full Text] [Related]
16. Platelet thrombus formation in eHUS is prevented by anti-MBL2. Kushak RI; Boyle DC; Rosales IA; Ingelfinger JR; Stahl GL; Ozaki M; Colvin RB; Grabowski EF PLoS One; 2019; 14(12):e0220483. PubMed ID: 31881024 [TBL] [Abstract][Full Text] [Related]
17. Interaction of Shiga toxin 2 with complement regulators of the factor H protein family. Poolpol K; Orth-Höller D; Speth C; Zipfel PF; Skerka C; de Córdoba SR; Brockmeyer J; Bielaszewska M; Würzner R Mol Immunol; 2014 Mar; 58(1):77-84. PubMed ID: 24317278 [TBL] [Abstract][Full Text] [Related]
18. Treatment of typical (enteropathic) hemolytic uremic syndrome. Bitzan M; Schaefer F; Reymond D Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636 [TBL] [Abstract][Full Text] [Related]
19. [Hemolytic uremic syndrome in children of Mendoza, Argentina: association with Shiga toxin-producing Escherichia coli infection]. Rivas M; Balbi L; Miliwebsky ES; García B; Tous MI; Leardini NA; Prieto MA; Chillemi GM; de Principi ME Medicina (B Aires); 1998; 58(1):1-7. PubMed ID: 9674201 [TBL] [Abstract][Full Text] [Related]
20. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome. Uchida H; Kiyokawa N; Horie H; Fujimoto J; Takeda T Pediatr Res; 1999 Jan; 45(1):133-7. PubMed ID: 9890621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]